FDA
-
-
-
-
-
-
-
Altai Capital pushes for OraSure board seats amid performance concerns
-
-
-
-
-
-
-
OraSure Announces Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
OraSure Technologies Acquires Sherlock Biosciences
-
-
-
-
-
-
-
OraSure Reports Q2 ’24 Revenue of $54.3 Million
-
-
-
-
-
-
-
OraSure Reports Q3 ‘23 Revenue of $89.2 Million; Core Revenue Grows 7% Year-over-Year
-
-
-
-
-
-
-
OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability
-
-
-
-
-
-
-
OraSure Technologies Receives General Clearance for its ORAcollect®•Dx Device for Over-the Counter (OTC) Use from the U.S. Food and Drug Administration (FDA)
-
329,187 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

